Impact Factor 4.137 | CiteScore 4.28
More on impact ›

Review ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Oncol. | doi: 10.3389/fonc.2019.01088

A Comparative Analysis of Individual RAS Mutations in Cancer Biology

  • 1Department of Radiation Oncology, University Hospital Bern, Switzerland
  • 2Department of BioMedical Research, Faculty of Medicine, University of Bern, Switzerland

In human cells, three closely related RAS genes, termed HRAS, KRAS and NRAS, encode four highly homologous proteins. RAS proteins are small GTPases involved in a broad spectrum of key molecular and cellular activities, including proliferation and survival among others. Gain-of-function missense mutations, mostly located at codons 12, 13 and 61, constitutively activate RAS proteins and can be detected in various types of human cancers. KRAS is the most frequently mutated, followed by NRAS and HRAS. However, each isoform exhibits distinctive mutation frequency at each codon, supporting the hypothesis that different RAS mutants may lead to distinct biologic manifestations. This review is focused on the differences in signaling and phenotype, as well as on transcriptomics, proteomics and metabolomics profiles-related to individual RAS-mutated variants. Besides, association of these mutants with particular targeted outcomes and rare mutations at additional RAS codons are discussed.

Keywords: RAS mutations, RAS profile, RAS-mutated cancers, Treatment responses, RAS-related omics, GTP/GDP binding, Ras signaling, rare codons

Received: 18 Aug 2019; Accepted: 02 Oct 2019.

Copyright: © 2019 Muñoz-Maldonado, Zimmer and Medová. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Dr. Michaela Medová, Department of Radiation Oncology, University Hospital Bern, Bern, 3010, Bern, Switzerland, michaela.medova@dbmr.unibe.ch